Viewing Study NCT02552550


Ignite Creation Date: 2025-12-24 @ 5:12 PM
Ignite Modification Date: 2026-01-03 @ 9:01 PM
Study NCT ID: NCT02552550
Status: TERMINATED
Last Update Posted: 2018-06-04
First Post: 2015-09-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx
Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Organization:

Study Overview

Official Title: Analysis of Swallowing, Speech and Quality of Life of Patients With Stage T3-T4 Squamous Cell Carcinoma of the Oropharynx Before and After Multimodal Treatment With Curative Intent
Status: TERMINATED
Status Verified Date: 2018-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: rate of inclusion too low
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The curative treatment and organ preservation in advanced squamous cell carcinoma of the oropharynx is multimodal. It involves induction chemotherapy and depending on the response radio-chemotherapy or surgery. The combination of these methods has important functional consequences.

The aim of this prospective pilot study is to describe swallowing, speech, but also patients' quality of life before and after therapeutic management (existing studies measuring these functions after treatment but not before).
Detailed Description: This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak then, as in normal practice, after 3, 6 and 12 months after treatment.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2012-A00904-39 OTHER ANSM View